NTX-2R13

N/A

Report date: 2022/05/10 11:44:59

Base Information

Drug NameNTX-2R13
Drug Alias NameNTX2R13
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTransmembrane protein PVRIG antagonistsT lymphocytes stimulants
TargetsTransmembrane protein PVRIG
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNectin Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNectin Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A